EquitySectoral/ ThematicRegularGrowthVery High

Tata India Pharma & Healthcare Fund

Q: What is the NAV of Tata India Pharma & Healthcare Fund?

As of 01 Oct 2026, the NAV of Tata India Pharma & Healthcare Fund is ₹32.16 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

Q: What returns has Tata India Pharma & Healthcare Fund delivered?

Tata India Pharma & Healthcare Fund has returned +6.39% over 1 year, +16.51% per year over 3 years, +12.34% per year over 5 years and +11.44% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

Q: What is the expense ratio of Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund charges an expense ratio of 2.41% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

Q: What are the top holdings of Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund's largest holdings are SUN PHARMACEUTICAL INDUSTRIES LTD (8.4%), HEALTHCARE GLOBAL ENTERPRISES LTD (6.3%), DIVI LABORATORIES LTD (5.7%), ABBOTT INDIA LTD (5.4%) and RAINBOW CHILDRENS MEDICARE LTD (4.5%). Holdings are disclosed monthly and change over time.

Q: How risky is Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 13.2% and its worst peak-to-trough fall in our sample was -21.9%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

Q: What does the Sharpe ratio of 0.76 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Tata India Pharma & Healthcare Fund's 0.76 means it has rewarded its volatility with excess return. Higher is better.

Q: What is the benchmark of Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund is benchmarked against the BSE Healthcare TRI. Its alpha and beta on this page are measured against that index.

Q: Who manages Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund is managed by Rajat Srivastava at Tata.

Q: How is Tata India Pharma & Healthcare Fund taxed?

Tata India Pharma & Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

Tata Mutual Fund · Best Sectoral & Thematic Mutual Funds

NAV

₹32.16

-0.64% 1D

as of 01 Oct 2026

This is the Regular plan of Tata India Pharma & Healthcare Fund — bought through a distributor, whose commission is paid out of its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.

Compare SIP calculator

Performance

+7.20%CAGR

52-week rangePrev NAV ₹32.37

Latest ₹32.16

Low ₹27.9170th percentile of its 52-week rangeHigh ₹34.00

Scorecard

★★★★☆4/5 vs 142 of 255 Sectoral/ Thematic peers

Performance 60%
Risk 15%
Cost 10%
Downside 15%

How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Sectoral/ Thematic (same plan and option). 142 of the 255 Sectoral/ Thematic funds in this cohort carry the full record the stars need, so they are the ones ranked against.

PerformanceStrong

3Y CAGR +16.51% · ranks 33 of 142 Sectoral/ Thematic funds

RiskLow

Volatility 13.2% vs 15.6% category avg

CostAverage

2.4% expense vs 2.5% category avg

ConsistencyModerate

87% of rolling 3Y windows were positive

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

Ahead of the Sectoral/ Thematic average on 1M/3M/6M/1Y — 1Y by 4.15pp
3-year return (+16.51%) beats the Sectoral/ Thematic average (+12.12%)
5-year return (+12.34%) beats the Sectoral/ Thematic average (+11.02%)
Stronger risk-adjusted returns — Sharpe 0.76 vs 0.34 Sectoral/ Thematic average
Less volatile than its Sectoral/ Thematic peers (13.2% vs 15.6%)

Concerns

No significant concerns identified.

Key Metrics

Annual fee charged by the fund, already deducted from NAV

2.41%

Category 2.46%▼0.05%

Portfolio-weighted harmonic mean P/E across the fund's equity holdings

45.28

Category —

Excess return per unit of total volatility (rf = 6.5%)

0.76

Category 0.34▲0.42

Scheme Info

Definitions

Plan

Regular · Growth

Period before units can be redeemed — 3 years for ELSS, none for most open-ended funds

None

0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.

0.25%

Statutory levy on every mutual-fund purchase since 1 Jul 2020 (SEBI / Govt of India) — the same for every scheme

0.005%

SIP Inv.

Allowed

Smallest recurring SIP instalment the scheme accepts

₹100

Smallest one-time (lumpsum) investment the scheme accepts

₹5,000

BSE Healthcare TRI

Start of our NAV history for this plan. Direct plans begin 1 Jan 2013, so this is the plan's inception — not necessarily the scheme's original launch date.

29 Dec 2015

Period returns (<1Y, absolute — not annualized)

Definitions

Absolute return over the last 1 month (not annualized)

-4.40%

Absolute return over the last 3 months (not annualized)

-0.50%

Absolute return over the last 6 months (not annualized)

+14.41%

Absolute return since 1 Jan of this year (not annualized)

+6.47%

Annualized returns (≥1Y — CAGR)

Definitions

1-year point-to-point return, annualized (CAGR)

+6.39%

3-year annualized return (CAGR)

+16.51%

5-year annualized return (CAGR)

+12.34%

10-year annualized return (CAGR)

+12.93%

Annualized return (CAGR) since the first NAV we hold for this plan — the Inception date under Key metrics. AMFI's history starts in April 2006, so an older scheme is measured from there.

+11.44%

Advanced metrics — risk and benchmark ratios

Risk (trailing 3Y)

Definitions

Annualized standard deviation of daily returns

13.21%

Excess return per unit of total volatility (rf = 6.5%)

0.76

Excess return per unit of downside deviation — upside swings aren't penalized (rf = 6.5%)

1.07

Largest peak-to-trough decline over full history

-21.94%

Benchmark ratios (vs Nifty 500 TRI · 36 monthly returns)

Definitions

Jensen's alpha (annualized): return above what CAPM predicts for the fund's beta vs Nifty 500 TRI

7.32%

Sensitivity to Nifty 500 TRI moves; 1 = moves with the index

0.80

How much of the fund's movement Nifty 500 TRI explains

56.4%

Excess return per unit of beta (market risk)

12.94

Active return over the benchmark per unit of tracking error

0.62

Annualized std dev of fund-minus-benchmark returns

11.50%

Fund's share of benchmark gains in up months (100 = matches index)

105.1%

Fund's share of benchmark losses in down months (lower is better)

69.7%

Computed vs the Nifty 500 TRI over the last 36 complete months — the closest match to this fund's mandate. TRI means dividends reinvested, as they are in the fund's own NAV; ₹ means a US index converted at each day's USD/INR, since the fund is priced in rupees. Needs ~3 years of history; a low R² means the fund tracks the index loosely.

Fund vs category average (Sectoral/ Thematic)

Period	Fund	Category avg.	Diff
1M abs	-4.40%	-5.14%	+0.74%
3M abs	-0.50%	-2.35%	+1.85%
6M abs	+14.41%	+10.80%	+3.61%
1Y CAGR	+6.39%	+2.24%	+4.15%
3Y CAGR	+16.51%	+12.12%	+4.39%
5Y CAGR	+12.34%	+11.02%	+1.32%

Category average across peers in Sectoral/ Thematic (254 of 255 carry a figure for at least one period), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Category rank

Vs 255 peers in Sectoral/ Thematic

1Y return

+6.39%

Beats 71.9% · rank #65

3Y return

+16.51%

Beats 77.3% · rank #33

5Y return

+12.34%

Beats 61.4% · rank #40

Sharpe

0.76

Beats 86.5% · rank #20

Sortino

1.07

Beats 87.9% · rank #18

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Monthly investment (₹)

Period

Invested

₹6.00L

Current value

₹8.62L

Absolute

+43.69%

XIRR

+14.94%

Value vs. invested

ValueInvested

60 monthly installments of ₹10,000 into Tata India Pharma & Healthcare Fund, valued at the latest NAV. XIRR annualizes for each installment’s timing.

Calendar-year returns

What the fund actually returned in each year, not the smoothed average.

Year	Fund	Nifty 500 TRI	Diff
2026part	+6.47%	-7.18%	+13.65%
2025	-4.92%	+7.94%	-12.86%
2024	+40.40%	+16.43%	+23.97%
2023	+36.58%	+27.43%	+9.15%
2022	-8.04%	+4.34%	-12.38%
2021	+19.07%	+31.59%	-12.52%
2020	+64.38%	+18.33%	+46.05%
2019	+5.51%	+8.95%	-3.44%
2018	-2.62%	-2.33%	-0.29%
2017	+4.65%	+37.35%	-32.70%

January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.

History points

2,652

Expense ratio

2.41%

AUM

₹1,278Cr

Portfolio turnover

49%

Exit load

0.25% of NAV if redeemed /switched out before 30 days from the date of allotment.

Portfolio, AUM & scheme details shown from another plan of this scheme (same underlying portfolio).

P/E ratio

45.3

P/B ratio

7.4

Avg market cap

₹93,463Cr

P/E & P/B are portfolio-weighted harmonic means across 32 of 41 equity holdings (81% of the portfolio); loss-making companies are excluded.

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)

20%

Held under 1 year

Flat, on the whole gain

Long-term (LTCG)

12.5%

Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Peer comparison · Sectoral/ Thematic

Compare all


Tata India Pharma & Healthcare FundThis fund Tata · Regular · Growth	★★★★☆	+6.39%	+16.51%	+12.34%	—	2.41%	—
Nippon India Taiwan Equity Fund Nippon India · Regular · Growth	★★★★☆	+118.60%	+60.45%	—	—	2.34%	₹1,110Cr
HDFC Defence Fund HDFC · Regular · Growth	★★★★☆	+21.45%	+34.62%	—	—	1.79%	₹9,371Cr
HDFC Pharma and Healthcare Fund HDFC · Regular · Growth	★★★★★	+25.19%	+28.72%	—	—	2.11%	₹2,282Cr
Franklin Asian Equity Fund Franklin Templeton · Regular · Growth	★★★☆☆	+32.21%	+22.88%	+8.49%	—	2.47%	₹720.84Cr
Aditya Birla Sun Life International Equity Fund Aditya Birla Sun Life · Regular · Growth	★★★★☆	+17.38%	+21.97%	+12.58%	—	2.54%	₹320.62Cr

Market-cap allocation · AMFI bands, Jul 2026

Equity holdings by company size — 100% of the equity sleeve priced.

Large cap23.4%
Mid cap39.3%
Small cap37.3%

Asset allocation

As on 31 Aug 2026 · AMC disclosure

Equity99.49%
Cash & Equivalents0.51%

Holds the same stocks as (by portfolio overlap, not by category)

Compare the top 3 →

Fund	Overlap	Rating	TER	3Y
Nippon India Pharma Fund Nippon India · Sectoral/ Thematic	57.2%	★★★★☆	1.00%	+17.58%
UTI - Healthcare Fund UTI · Sectoral/ Thematic	56.2%	★★★★☆	1.34%	+22.50%
ITI Pharma and Healthcare Fund ITI · Sectoral/ Thematic	56.2%	★★★★★	0.89%	+18.84%
Bandhan BSE Healthcare Index Fund Bandhan · Index Funds	53.9%	★★★★★	0.34%	—
Aditya Birla Sun Life Pharma and Healthcare Fund Aditya Birla Sun Life · Sectoral/ Thematic	51.8%	★★★★★	1.05%	+20.06%
Bandhan Healthcare Fund Bandhan · Sectoral/ Thematic	50.0%	—	1.25%	—
SBI Healthcare Opportunities Fund SBI · Sectoral/ Thematic	48.5%	★★★★★	1.01%	+22.78%
Mirae Asset Healthcare Fund Mirae Asset · Sectoral/ Thematic	48.3%	★★★★★	0.62%	+21.71%

Overlap is the share of each fund's equity book invested in the same stocks, by weight, across the Direct-plan universe — so a fund that is only part equity is labelled as such. ! marks a pair holding more in common than nine pairs in ten of its type, where that type has a measured distribution.

Worst falls, and the wait to get back

How far this fund has dropped from a high, and how long it took to reclaim it.

-21.9%01 Feb 2016 → 05 Jun 2018
Fell over 2.3 years, back to the old high on 19 Feb 2020 — 1.7 years under water after the low.
-18.6%19 Feb 2020 → 23 Mar 2020
Fell over 33 days, back to the old high on 08 Apr 2020 — 16 days under water after the low.
-18.2%15 Sep 2021 → 17 Jun 2022
Fell over 9 months, back to the old high on 05 Jul 2023 — 13 months under water after the low.

Measured on this fund’s own NAV history, peak to trough to the day it regained the peak. Falls shallower than 5% are left out. A recovery date is when the NAV got back, not when any particular investor did — that depends on when they bought.

AMC Profile

Tata Mutual Fund is run by Tata Asset Management, part of the Tata Group, and has been in business since 1995. It runs a broad line-up across equity, debt and hybrid, including several long-running thematic schemes.

Launched

29 Jun 1995

Total AUM

₹2,36,199Cr+3.4% QoQ

Avg AUM · July - September 2026

Website

tatamutualfund.com

Fund Managers

RSRajat SrivastavaStart date not disclosed

Education

BBA (Banking & Insurance), Ghaziabad

All schemes Rajat Srivastava runs →

Fund manager, benchmark and dealing terms from this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.

Explore from here

Top holdings

SUN PHARMACEUTICAL INDUSTRIES LTD HEALTHCARE GLOBAL ENTERPRISES LTD DIVI LABORATORIES LTD ABBOTT INDIA LTD RAINBOW CHILDRENS MEDICARE LTD APOLLO HOSPITALS ENTERPRISE LTD CIPLA LTD DR REDDYS LABORATORIES LTD MAX HEALTHCARE INSTITUTE LTD FORTIS HEALTHCARE LTD LUPIN LTD SYNGENE INTERNATIONAL LTD

Tata in the news

Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.

Run SIP calculator Add to compare

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Sectoral & Thematic funds

Sectoral and thematic funds must keep at least 80% in the equity of one sector (banking, pharma, technology) or one theme (consumption, manufacturing, ESG). That concentration is the point and the risk: with no mandate to diversify away from the sector, the fund rises and falls with it.

Frequently asked questions

What is the NAV of Tata India Pharma & Healthcare Fund?

As of 01 Oct 2026, the NAV of Tata India Pharma & Healthcare Fund is ₹32.16 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has Tata India Pharma & Healthcare Fund delivered?

Tata India Pharma & Healthcare Fund has returned +6.39% over 1 year, +16.51% per year over 3 years, +12.34% per year over 5 years and +11.44% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund charges an expense ratio of 2.41% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund's largest holdings are SUN PHARMACEUTICAL INDUSTRIES LTD (8.4%), HEALTHCARE GLOBAL ENTERPRISES LTD (6.3%), DIVI LABORATORIES LTD (5.7%), ABBOTT INDIA LTD (5.4%) and RAINBOW CHILDRENS MEDICARE LTD (4.5%). Holdings are disclosed monthly and change over time.

How risky is Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 13.2% and its worst peak-to-trough fall in our sample was -21.9%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What does the Sharpe ratio of 0.76 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Tata India Pharma & Healthcare Fund's 0.76 means it has rewarded its volatility with excess return. Higher is better.

What is the benchmark of Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund is benchmarked against the BSE Healthcare TRI. Its alpha and beta on this page are measured against that index.

Who manages Tata India Pharma & Healthcare Fund?

Tata India Pharma & Healthcare Fund is managed by Rajat Srivastava at Tata.

How is Tata India Pharma & Healthcare Fund taxed?

Tata India Pharma & Healthcare Fund is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.